Lukas Hainz

The complexity of biological systems often leaves pharmaceutical researchers grappling with a vast "dark matter" of untreatable conditions, where nearly 90% of human biology remains untouched by current therapeutic interventions. This systemic limitation has historically led to a high-risk and

The global marketplace for pharmaceuticals has reached a critical inflection point where the sheer volume of counterfeit medications now threatens the fundamental integrity of international healthcare systems and patient safety alike. As criminal networks become more sophisticated in replicating

The global healthcare landscape is currently confronting a transformative challenge that necessitates a fundamental shift in how we approach chronic and life-threatening illnesses. With projections from the American Cancer Society suggesting that global cancer cases could reach 35 million annually

Lukas Hainz sits down with Ivan Kairatov, a distinguished biopharma expert with a deep background in research and development and a keen eye for technological innovation within the pharmaceutical industry. Together, they explore a recent breakthrough from the University of Cambridge that reimagines

The relentless pursuit of highly effective oncological interventions has historically been hampered by the inability of traditional pharmaceutical agents to distinguish accurately between malignant cells and healthy physiological structures. While chemotherapy and systemic radiation have saved

The relentless physical and psychological burden of chronic cholestatic pruritus often defines the daily existence of patients long before a clinical diagnosis is even finalized. For those living with rare liver diseases, the sensation of an internal, unreachable itch is not merely a symptom but a

The landscape of gastrointestinal oncology has shifted significantly as European regulators authorize a potent new weapon for combating aggressive tumors before they have the chance to spread. The European Commission has officially approved the use of AstraZeneca’s durvalumab, commercially known as

The boundaries between how a cell generates energy and how it decides to multiply have long been viewed as separate chapters in the book of biology, yet recent evidence suggests these processes are inextricably linked by a single, versatile protein. For over seventy years, scientists categorized

Ivan Kairatov brings a wealth of experience from the front lines of biopharma research and development, where the intersection of technology and biology is fundamentally reshaping patient care. His deep understanding of how innovation transitions from the laboratory to the clinical bedside makes

The subtle transformation of a single protein’s physical structure within the human circulatory system may hold the definitive key to identifying Alzheimer’s disease years before the first signs of cognitive decline begin to surface in a patient. While the medical community has long focused on the